Smoking outcome by psychiatric history after behavioral and varenicline treatment

Jennifer B. McClure, Gary E. Swan, Sheryl L Catz, Lisa Jack, Harold Javitz, Tim McAfee, Mona Deprey, Julie Richards, Susan M. Zbikowski

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Treatment outcomes were compared across smokers enrolled in the COMPASS cessation trial with (positive psychiatric history [PH+], n = 271) and without (PH-, n = 271) a diagnosis of PH based on medical record evidence of anxiety, depression, psychotic disorder, or bipolar disorder. Everyone received behavioral counseling plus varenicline and was followed for 6 months post quit date. PH+ smokers took varenicline for fewer days on average (59.4 vs. 68.5, p ≤ .01) but did not differ in their use of behavioral treatment. PH+ smokers were more likely to report anxiety and depression, but side-effect intensity ratings did not differ after adjusting for multiple comparisons. Overall, all side effects were rated as moderate intensity or less. Groups had similar 30-day abstinence rates at 6 months (31.5% PH+ vs. 35.4% PH-, p = .35). In sum, having a psychiatric diagnosis in this trial did not predict worse treatment outcome or worse treatment side effects.

Original languageEnglish (US)
Pages (from-to)394-402
Number of pages9
JournalJournal of Substance Abuse Treatment
Issue number4
StatePublished - Jun 2010
Externally publishedYes


  • Anxiety
  • Depression
  • Psychiatric illness
  • Side effects
  • Smoking cessation
  • Varenicline

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Phychiatric Mental Health
  • Medicine (miscellaneous)


Dive into the research topics of 'Smoking outcome by psychiatric history after behavioral and varenicline treatment'. Together they form a unique fingerprint.

Cite this